Audrey Kunin - 05 Nov 2021 Form 3 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role
Chief Product Officer
Signature
/s/ Audrey Kunin
Issuer symbol
NBY
Transactions as of
05 Nov 2021
Net transactions value
$0
Form type
3
Filing time
17 Nov 2021, 19:15:29 UTC
Next filing
24 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NBY Common Stock 0 05 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NBY Stock option (right to buy) 05 Nov 2021 Common Stock 150,000 $0.5597 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option grant will vest in two tranches, with 50% vesting on November 5, 2022 and 50% vesting on November 5, 2023.